"A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation)"

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

April 20, 2020

Study Completion Date

April 20, 2020

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
BIOLOGICAL

Eculizumab (JSC GENERIUM, Russia)

Eculizumab

Trial Locations (9)

125167

"Federal State Budgetary Institution National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation", Moscow

125284

State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin of the Moscow Department of Health, Moscow

129110

"State budgetary institution of health care of the Moscow region Moscow Regional Research Clinical Institute named after M.F. Vladimirsky", Moscow

197022

"Federal State Budgetary Educational Institution of Higher Education First St. Petersburg State Medical University named after Academician I.P. Pavlov", Saint Petersburg

344015

"State budgetary institution of the Rostov region Rostov Regional Clinical Hospital", Rostov-on-Don

443099

"Federal State Budgetary Educational Institution of Higher Education Samara State Medical University of the Ministry of Health of the Russian Federation", Samara

454076

"State budgetary healthcare institution Chelyabinsk Regional Clinical Hospital", Chelyabinsk

610027

"Federal State Budgetary Institution of Science Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency", Kirov

620102

"State Budgetary Healthcare Institution of the Sverdlovsk Region Sverdlovsk Regional Clinical Hospital No. 1", Yekaterinburg

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT04679103 - "A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation)" | Biotech Hunter | Biotech Hunter